{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:29:42Z","timestamp":1789475382996,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C50947\/A18176"],"award-info":[{"award-number":["C50947\/A18176"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC2044"],"award-info":[{"award-number":["CC2044"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["A2204"],"award-info":[{"award-number":["A2204"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["686061"],"award-info":[{"award-number":["686061"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000098","name":"National Institutes of Health Clinical Center","doi-asserted-by":"publisher","award":["U01 CA247439"],"award-info":[{"award-number":["U01 CA247439"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016916","name":"Royal Marsden Cancer Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"The National Institute for Health Research Biomedical Research Centre for cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000650","name":"Institute of Cancer Research","doi-asserted-by":"publisher","award":["A109"],"award-info":[{"award-number":["A109"]}],"id":[{"id":"10.13039\/501100000650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejca.2022.12.011","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T20:14:23Z","timestamp":1671480863000},"page":"15-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6208-173X","authenticated-orcid":false,"given":"Scott T.C.","family":"Shepherd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samra","family":"Turajlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5112","key":"10.1016\/j.ejca.2022.12.011_bib1","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.011_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/jmedgenet-2016-104058","article-title":"Survival and causes of death in patients with von Hippel-Lindau disease","volume":"54","author":"Binderup","year":"2017","journal-title":"J Med Genet"},{"issue":"283","key":"10.1016\/j.ejca.2022.12.011_bib3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/qjmed\/77.2.1151","article-title":"Clinical features and natural history of von Hippel-Lindau disease","volume":"77","author":"Maher","year":"1990","journal-title":"Q J Med"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.011_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrc3844","article-title":"VHL, the story of a tumour suppressor gene","volume":"15","author":"Gossage","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.12.011_bib5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.15586\/jkcvhl.2014.12","article-title":"Pathological and clinical features and management of central nervous system hemangioblastomas in von Hippel-lindau disease","volume":"1","author":"Kanno","year":"2014","journal-title":"J Kidney Cancer VHL"},{"issue":"6","key":"10.1016\/j.ejca.2022.12.011_bib6","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3171\/2014.10.JNS131602","article-title":"Stereotactic radiosurgery for intracranial hemangioblastomas: a retrospective international outcome study","volume":"122","author":"Kano","year":"2015","journal-title":"J Neurosurg"},{"issue":"5","key":"10.1016\/j.ejca.2022.12.011_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(02)00071-5","article-title":"HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron","volume":"1","author":"Mandriota","year":"2002","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.ejca.2022.12.011_bib8","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0022-5347(01)66674-6","article-title":"Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications","volume":"154","author":"Walther","year":"1995","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.011_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.juro.2010.09.032","article-title":"Feasibility and outcomes of partial nephrectomy for resection of at least 20 tumors in a single renal unit","volume":"185","author":"Fadahunsi","year":"2011","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ejca.2022.12.011_bib10","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.juro.2010.01.010","article-title":"Repeat partial nephrectomy on the solitary kidney: surgical, functional and oncological outcomes","volume":"183","author":"Liu","year":"2010","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.011_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.juro.2008.03.030","article-title":"Feasibility and outcomes of repeat partial nephrectomy","volume":"180","author":"Johnson","year":"2008","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ejca.2022.12.011_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/ncpuro0179","article-title":"Management of von Hippel-Lindau-associated kidney cancer","volume":"2","author":"Grubb","year":"2005","journal-title":"Nat Clin Pract Urol"},{"issue":"7","key":"10.1016\/j.ejca.2022.12.011_bib13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/neuonc\/nov313","article-title":"Von Hippel-Lindau disease: an evaluation of natural history and functional disability","volume":"18","author":"Feletti","year":"2016","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.011_bib14","first-page":"1","article-title":"Benefits of screening in von Hippel-Lindau disease--comparison of morbidity associated with initial tumours in affected parents and children","volume":"66","author":"Priesemann","year":"2006","journal-title":"Horm Res"},{"issue":"4","key":"10.1016\/j.ejca.2022.12.011_bib15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jmedgenet-2011-100562","article-title":"Life expectancy in hereditary cancer predisposing diseases: an observational study","volume":"49","author":"Wilding","year":"2012","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.011_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF axis in clear cell renal carcinoma","volume":"23","author":"Shen","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"10.1016\/j.ejca.2022.12.011_bib17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cell.2018.02.020","article-title":"Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal","volume":"173","author":"Mitchell","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ejca.2022.12.011_bib18","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2022.12.011_bib19","series-title":"FDA approves belzutifan for cancers associated with von Hippel-Lindau disease","author":"Administration","year":"2021"},{"key":"10.1016\/j.ejca.2022.12.011_bib20","series-title":"Summary of product characteristics","author":"Agency","year":"2022"},{"issue":"22","key":"10.1016\/j.ejca.2022.12.011_bib21","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel\u2013lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2022.12.011_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2022.12.011_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"issue":"9605","key":"10.1016\/j.ejca.2022.12.011_bib24","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejca.2022.12.011_bib25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejca.2022.12.011_bib26","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/annonc\/mdr011","article-title":"Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease","volume":"22","author":"Jonasch","year":"2011","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.12.011_bib27","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S1470-2045(18)30487-X","article-title":"Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial","volume":"19","author":"Jonasch","year":"2018","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.ejca.2022.12.011_bib28","doi-asserted-by":"crossref","first-page":"23390","DOI":"10.18632\/oncotarget.25171","article-title":"Pilot study of dovitinib in patients with von Hippel-Lindau disease","volume":"9","author":"Pilie","year":"2018","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.ejca.2022.12.011_bib29","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1038\/sj.emboj.7601300","article-title":"Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo","volume":"25","author":"Kim","year":"2006","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.ejca.2022.12.011_bib30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/2159-8290.CD-11-0098","article-title":"Genetic and functional studies implicate HIF1\u03b1 as a 14q kidney cancer suppressor gene","volume":"1","author":"Shen","year":"2011","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.ejca.2022.12.011_bib31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1073\/pnas.0808092106","article-title":"Artificial ligand binding within the HIF2alpha PAS-B domain of the HIF2 transcription factor","volume":"106","author":"Scheuermann","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ejca.2022.12.011_bib32","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm301847z","article-title":"Development of inhibitors of the PAS-B domain of the HIF-2alpha transcription factor","volume":"56","author":"Rogers","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejca.2022.12.011_bib33","article-title":"1447O - phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): cohort 1 of LITESPARK-003","author":"J","year":"2022","journal-title":"ESMO congress 2022"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.12.011_bib34","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2021.39.15_suppl.4555","article-title":"Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC)","volume":"39","author":"Srinivasan","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.12.011_bib35","series-title":"Belzutifan for treating clear-cell renal carcinoma caused by von Hippel-Lindau disease","author":"Excellence","year":"2022"},{"key":"10.1016\/j.ejca.2022.12.011_bib36","series-title":"Public summary of opinion on orphan designation 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H- inden-4-yl)oxy)-5-fluorobenzonitrile for the treatment of von Hippel-Lindau disease","author":"Agency","year":"2020"},{"key":"10.1016\/j.ejca.2022.12.011_bib37","doi-asserted-by":"crossref","first-page":"S1303","DOI":"10.1016\/j.annonc.2021.08.2104","article-title":"LBA28 star: a randomised multi-stage phase II\/III trial of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and\/or metastatic renal Cancer (RCC)","volume":"32","author":"Brown","year":"2021","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2022.12.011_bib38","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.18.02142","article-title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update","volume":"37","author":"Bohlius","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.12.011_bib39","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/bjd.16270","article-title":"Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum","volume":"178","author":"Salomon","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2022.12.011_bib40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2017.02.026","article-title":"Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab","volume":"77","author":"Hauschild","year":"2017","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2022.12.011_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2022.12.011_bib42","series-title":"Establish a clinical care center","author":"Alliance","year":"2022"},{"issue":"9","key":"10.1016\/j.ejca.2022.12.011_bib43","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41416-022-01724-7","article-title":"Evaluation of tumour surveillance protocols and outcomes in von Hippel-Lindau disease in a national health service","volume":"126","author":"Maher","year":"2022","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.12.011_bib44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/bmjinnov-2020-000440","article-title":"Telemedicine takes centre stage\u00a0during COVID-19 pandemic","volume":"6","author":"Ahmed","year":"2020","journal-title":"BMJ Innovations"},{"issue":"5.5","key":"10.1016\/j.ejca.2022.12.011_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6004\/jnccn.2022.5020","article-title":"The future of telemedicine in oncology","volume":"20","author":"Langer","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ejca.2022.12.011_bib46","doi-asserted-by":"crossref","first-page":"S1433","DOI":"10.1016\/j.annonc.2022.08.074","article-title":"LBA69 Belzutifan, a HIF-2\u03b1 Inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: 36 months of follow-up of the phase II LITESPARK-004 study","volume":"33","author":"Srinivasan","year":"2022","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922018135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922018135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:35:00Z","timestamp":1778517300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922018135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":46,"alternative-id":["S0959804922018135"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.011","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}